



Original article

Platelet activation and thrombus formation relates to the presence of myocardial inflammation in patients with cardiomyopathy



Peter Bobbert (MD), Ulf Weikert (MD), Caroline Schmidt-Lucke (MD), Carsten Skurk (MD), Alexander Meyer, Daniel Steffens, Heinz Peter Schultheiss (MD), Ursula Rauch (MD)*

Department of Cardiology and Pneumology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany

ARTICLE INFO

Article history:

Received 21 March 2013
Received in revised form 6 August 2013
Accepted 18 September 2013
Available online 11 November 2013

Keywords:

Cardiomyopathy
Platelet activation
Myocardial inflammation

ABSTRACT

Background: Patients with cardiomyopathy show a significantly increased risk for thromboembolic events due to a hypercoagulable state and platelet dysfunction. The pathophysiologic mechanism underlying the increasing platelet activity in patients with cardiomyopathy remains unclear. We performed a clinical study to elucidate the link between myocardial tissue alterations and platelet activation in patients with cardiomyopathy.

Methods: A total of 30 patients with suspected cardiomyopathy and 10 healthy control patients were included in our study. Hemodynamic parameters were measured by catheterization and echocardiography. Endomyocardial biopsies were taken to determine myocardial inflammation. Flow cytometry was performed to examine the platelet activation by quantification of p-selectin and thrombospondin expression on platelets.

Results: The p-selectin (8.46 ± 3.67 AU) and thrombospondin (26.56 ± 23.21 AU) expression was significantly correlated with the amount of CD3+ T cells (p-selectin: $r=0.573$, $p<0.05$; thrombospondin: $r=0.488$, $p<0.05$) and the endothelial/interstitial activation (p-selectin: $r=0.521$, $p<0.05$; thrombospondin: $r=0.39$, $p<0.05$). This was found to be independent of hemodynamic parameters, age, and gender. The platelet activation of patients ($n=3$) with echocardiographically documented ventricular thrombi was significantly increased (p-selectin: 12.57 ± 5.5 AU vs. 8.1 ± 3.2 AU, $p<0.05$) and this was associated with elevated myocardial inflammation scores.

Conclusion: Myocardial inflammation is associated with a significant increase in platelet activation and ventricular thrombus formation independently of the hemodynamic conditions.

© 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Introduction

Non-ischemic cardiomyopathy (CM) is a serious disorder leading to high morbidity and mortality because of arrhythmic events and sudden death [1]. The myocardial disorder is characterized by an impaired systolic or diastolic heart function combined with changes in ventricular diameters and pressures. These alterations predispose to ventricular thrombus formation with increased risk for stroke, peripheral arterial occlusion, and pulmonary embolism [2].

The etiology of CM includes various factors such as myocardial viral infections, genetic variations, autoimmune disorders, or toxic agents. After exclusion of a possible ischemic genesis for impaired cardiac function, CMs are classified into 5 groups according to their ventricular diameters, intra-ventricular

pressures, and myocardial tissue alterations: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and unspecified cardiomyopathies (UCM) [3,4].

DCM is characterized by impaired contractile heart function and ventricular chamber enlargement. One important causal factor for the development of DCM is the presence of a myocardial viral infection, triggering inflammatory processes such as increased inflammatory cytokine and chemokine expression as well as infiltration of proinflammatory T cells and macrophages. A chronic state of these inflammatory processes might result in myocardial alterations as defined by the existence of DCM.

Higher rates of ischemic strokes in patients with symptoms of heart failure have already been demonstrated [5]. As described by the “Virchow Triad” abnormal blood flow, vessel wall abnormalities, and pathologic changes in blood constituents may lead to an increased risk of thrombogenesis [6]. Thus far, clinical studies have failed to show a direct relation between only depressed hemodynamic conditions and thromboembolic events, pointing

* Corresponding author. Tel.: +49 30 8445 2362; fax: +49 30 8445 4648.
E-mail address: ursula.rauch@charite.de (U. Rauch).

to additional pathophysiologic alterations that mediate blood hypercoagulability in patients with CM. Therefore, clear guidelines about the necessity of anticoagulant therapies in patients with non-ischemic CM are still missing [7].

A pro-thrombotic state is at least in part characterized by increased platelet activation [8–10]. Patients with CM have already been reported to have significant abnormalities in platelet function, that contribute to a hypercoagulable state [11]. Chronic cardiac tissue alterations including increased myocardial inflammation and vascular constriction have been suggested to contribute to endothelial and platelet dysfunction in cases of CM [12,13].

Thus our clinical study was performed to elucidate the link between myocardial alterations and platelet function. Therefore, platelet activation was assessed by quantification of activation-dependent protein expression on the platelet surface in patients with suspected CM and correlated with markers of endothelial activation and myocardial inflammation.

Methods

Study design

A total of 30 patients with suspected non-ischemic CM and 10 healthy control patients were included in our study, considering medical history, symptoms, physical examination, and non-invasive test. The patients were enrolled into the study if they had both (1) clinically suspected CM by history and symptoms (dyspnea or exercise intolerance, angina, and palpitations) or by history and electrocardiographic changes (rhythm disturbances, ST-segment, or T-wave deviations) and (2) echocardiographic findings of left ventricular dysfunction (regional wall motion abnormalities or global left ventricular dysfunction). The presence of coronary artery disease was excluded in all patients with coronary angiography. Left ventricular ejection fraction (LVEF) was determined by left ventricular catheterization and ventriculography. Right ventricular catheterization was performed in all patients to take endomyocardial biopsies from the right ventricular septum with a standard biptome. Patients with severe respiratory infections, tumor disease, renal insufficiency, hematological disorders or other severe disease were excluded from the study. Furthermore, echocardiographic analysis was performed at the time of enrollment to assess left ventricular end-diastolic diameters (LVEDD), left atrium diameter, and to detect possible ventricular thrombus formation. Patients were classified into 4 groups of non-ischemic CM according to their hemodynamic and cardiac inflammatory characteristics: (1) DCM without inflammation (LVEF < 50%, LVEDD > 55 mm, negative cardiac inflammation score); (2) DCM with inflammation (DCMi: LVEF < 50%, LVEDD > 55 mm, positive cardiac inflammation score); (3) CM with inflammation (CMi: LVEF ≥ 50%, LVEDD < 55 mm, positive cardiac inflammation score); (4) UCM (LVEF ≥ 50%, LVEDD < 55 mm, negative cardiac inflammation score, symptoms of heart failure or electrocardiographic changes). A positive myocardial inflammation score was defined according to the Dallas criteria and criteria of the World Heart Federation (WHF) [14].

The study protocol was approved by the local ethics committee. It was performed in accordance with the ethics principles in the Declaration of Helsinki. Written informed consent was provided by each patient before participation in the study.

Immunohistochemical assessment of myocardial biopsies

Myocardial biopsies were prepared and evaluated as previously described. HLA-1, HLA-DR, and ICAM-1 were evaluated as markers for activation of endothelial and interstitial cells within the

myocardial tissue. Expression of HLA-1, HLA-DR, and ICAM-1 on endothelial and interstitial cells was semiquantitatively scaled 0 (normal), 1 (intense), 2 (abundant), 3 (very abundant) according to the intensity of immunoperoxidase staining of the cells [15]. The activation of the endothelial and interstitial cells was graded according to the sum of HLA-1, HLA-DR, and ICAM-1 expression on each cell type (minimum: 0; maximum: 18). Further cellular infiltrates (CD3+ cells, CD45+ cells, and activated macrophages) within the myocardial tissue were also assessed as a measure of myocardial inflammation as previously described [16,17].

Measurement of in vivo platelet degranulation

Venous blood was drawn from all patients into a platelet-stabilizing agent containing 134 mmol ethylenediaminetetraacetic acid and 20 units heparin (ratio 9 volumes blood plus 1 volume reagent). The blood was immediately fixed in 0.5% paraformaldehyde (pH 7.4). Platelet-rich plasma was prepared for the measurement of in vivo platelet degranulation as described before [18]. The platelets were incubated with mouse IgG (unspecific binding) or a monoclonal antibody against p-selectin, thrombospondin, or fibrinogen (all antibodies from Coulter Immunotech, Marseille, France), followed by a secondary fluorescein isothiocyanate-labeled antibody (SIGMA, St Louis, MO, USA). Flow cytometry was thereafter performed (FACScan, Becton Dickinson, San José, CA, USA) as previously described [19–21].

Statistical analysis

SPSS statistical software version 16.0 (Chicago, IL, USA) was used for all statistical analyses. Graphical illustrations were done by SPSS statistical software version 16.0 and GraphPad Prism Version 4.03 (San Diego, CA, USA). All data were expressed as the mean ± standard deviation (SD), except for data in the figures that are presented as the mean ± standard error of the mean (SEM). A *p*-value < 0.05 was regarded as statistically significant. Quantitative variables with normal distribution were analyzed with Student's *t*-test, and variables without normal distribution with a two-tailed Mann–Whitney *U*-test. The correlation analyses were performed with Pearson's and Spearman's test. Bonferroni's correction was not performed. Multivariate linear regression was calculated to analyze the factors independently affecting specific variants. An α error < 5% was considered statistically significant. Our multivariate linear regression was performed as a stepwise backward elimination process, deleting statistically non-significant parameters subsequently. Possible multicollinearity was tested by determination of the variance inflation factor (VIF) and the tolerance of each included parameter. A VIF > 5 was regarded as a critical sign of existing multicollinearity.

Results

Thirty patients with non-ischemic CM were included during the study period. Patient characteristics are shown in Table 1, demonstrating hemodynamic and myocardial inflammation patterns of the study patients. A total of 7 patients were classified into the DCM group, 7 patients into the DCMi group, 8 patients into the CMi group, and 8 patients into the UCM group. The platelet activation was evaluated by flow cytometry and the expression of p-selectin (8.46 ± 3.67 AU), thrombospondin (26.56 ± 23.21 AU), and fibrinogen (25.47 ± 8.62) on the platelet surface was quantified (Fig. 1). Compared to a healthy control group ($n = 10$), p-selectin (5.8 ± 1.99 AU, $p < 0.05$), thrombospondin (12.8 ± 9.21 AU, $p < 0.05$), and fibrinogen (14.1 ± 3.55 AU, $p < 0.05$) expression were significantly increased in patients with non-ischemic CM.

Table 1
Patient characteristics.

Study patients n = 30	
Sex (female/male)	5/25
Age (years)	48.2 ± 13
LVEF (%)	45.4 ± 17
LVEDD (mm)	62.7 ± 11
CD3+ T cells (n/mm ²)	2.69 ± 2
CD45+ T cells (n/mm ²)	1.29 ± 2
Interstitial activation	4.22 ± 1.3
Endothelial activation	4.27 ± 1.2
Hemoglobin (g/dL)	14.01 ± 0.6
Hematocrit (%)	41 ± 2.6
Leucocytes (n/mL)	7.3 ± 1.1
Platelets (n/nL)	319 ± 54.8

LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter.

A reduced left ventricular ejection fraction did not lead to significantly different p-selectin, thrombospondin, and fibrinogen expression patterns. In contrast, patients with increased endothelial and interstitial activation had an increased p-selectin and thrombospondin expression on platelets (Fig. 1).

As demonstrated in Figs. 2A and 3A, the platelet expression of p-selectin as well as thrombospondin was significantly correlated with the activation of cardiac interstitial and endothelial cells (p-selectin: $r = 0.521$, $p < 0.05$; thrombospondin: $r = 0.39$, $p < 0.05$) and with myocardial inflammation as assessed by CD3+ T cells

(p-selectin: $r = 0.573$, $p < 0.05$; thrombospondin: $r = 0.488$, $p < 0.05$). Moreover, activation of cardiac interstitial and endothelial cells was correlated significantly with the amount of myocardial CD3+ T cells ($r = 0.452$, $p < 0.05$). A multivariate linear regression model was performed to demonstrate the effect of myocardial inflammation and endothelial/interstitial activation on the p-selectin and thrombospondin expression on platelets (Table 2). Various parameters such as hemodynamic values (LVEF, LVEDD), cardiac inflammation scores (CD3+ T cells, CD45+ T cells, interstitial/endothelial activation), and patient characteristics (age, gender) were included in the model. After subsequent exclusion of non-significant variants the amount of CD3+ T cells and the myocardial interstitial/endothelial activation were found as the only parameters with appropriate impact on platelet activation (Table 2). Both parameters accounted for ~30% of the variation of p-selectin or for ~28% of the variation of thrombospondin expression in our model.

Ventricular thrombus formation was documented by echocardiography in three patients of the study population. All of them showed a significantly increased p-selectin platelet expression compared to patients without ventricular thrombus (Fig. 2B; with thrombus: 12.57 ± 5.5 AU; without thrombus: 8.01 ± 3.2 AU, $p < 0.05$). The thrombospondin expression on platelets in patients with ventricular thrombus formation was also increased in tendency (Fig. 3B; with thrombus: 49.6 ± 25 AU; without thrombus: 24 ± 22 , $p = 0.069$). As illustrated in Figs. 2A and 3A patients with ventricular thrombus showed an above average elevated platelet activation that was associated with increased cardiac inflammation and endothelial activation.




Fig. 1. Platelet activation demonstrated by p-selectin, thrombospondin, and fibrinogen expression. Expression of activation markers on platelets was assessed by flow cytometry. Results were expressed in scatter dot blots (top line). Patients were divided into 2 groups according to left ventricular ejection fraction (LVEF) (<50%, $n = 14$ vs. $\geq 50\%$, $n = 16$) and to the endothelial and interstitial activation (≤ 8 , $n = 15$ vs. > 8 , $n = 15$) to demonstrate p-selectin, thrombospondin, and fibrinogen expression patterns in these groups (bottom line). Data are presented as mean ± SEM.




Fig. 2. P-selectin expression is associated with cardiac inflammation. (A) Correlations between p-selectin expression with endothelial/interstitial activation and CD3+ T cells are shown in scatter blots. Patients with thrombus formation were marked with black points. (B) P-selectin expression on platelets is demonstrated according to the incidence of ventricular thrombus formation (yes: with thrombus, $n=3$; no: without thrombus: $n=27$). Data are presented as mean \pm SEM.




Fig. 3. Thrombospondin expression is associated with cardiac inflammation. (A) Correlations between thrombospondin expression with endothelial/interstitial activation and CD3+ T cells are shown in scatter blots. Patients with thrombus formation were marked with black points. (B) Thrombospondin expression on platelets is demonstrated according to the incidence of ventricular thrombus formation (yes: with thrombus, $n=3$; no: without thrombus: $n=27$). Data are presented as mean \pm SEM.

Table 2

Multivariate linear regression model for platelet activation markers. Linear regression was calculated after inclusion of potential covariants. Non-significant covariants such as left ventricular ejection fraction, left ventricular end-diastolic diameter, age, gender and CD45+ T cells were subsequently excluded, leaving the amount of CD3– T cells and endothelial/interstitial activation as contributors for the most efficient model. The multiplicative term (correlation \times standardized $\beta \times 100$) explains the variation of p-selectin or thrombospondin illustrated by the respective parameter in per cent.

	Correlation	Standardized β	Correlation \times standardized $\beta \times 100$	p-Value
<i>P-selectin</i>				
Endothelial/interstitial activation	0.359	0.33	11.8	0.056
CD3+ T Cells	0.443	0.424	18.8	0.016
<i>Thrombospondin</i>				
Endothelial/interstitial activation	0.383	0.411	15.7	0.049
CD3+ T Cells	0.359	0.338	12.1	0.066

Discussion

This study examined the association between myocardial inflammation and platelet activation in patients with suspected non-ischemic CM. Positive correlations were demonstrated in patients with CM between increased p-selectin and thrombospondin expression as markers of platelet activation and myocardial inflammation.

Despite the well acknowledged hypercoagulability in patients with CMs and reduced heart function, larger clinical trials failed to demonstrate the benefit of anticoagulant therapies in patients with impaired ejection fraction. The WARCEF and the WATCH trials did not find any evidence to support the use of oral anticoagulant medications in patients with CMs and reduced LVEF [22,23], pointing to the necessity to describe further characteristics that help to predict the individual risk of thrombotic events [24,25]. These parameters might be useful to detect patients with CMs independent of their left ventricular function who benefit from an anticoagulant therapy. Current guidelines do not recommend in general the use of oral anticoagulation in patients with DCM [26,27].

Patients with DCM present a systemic hypercoagulable state with increased circulating fibrinogen and d-dimer blood levels [28,29]. Furthermore, increased systemic von Willebrand factor expression as well as elevated concentrations of fibrinopeptide A and thrombin–antithrombin complexes are demonstrated in these patients as indicators for a prothrombotic condition. The missing link between reduced ventricular function and the prothrombotic state in patients with CM supports our hypothesis of further characteristics with procoagulant impact on the coagulation system. Therefore, we elucidated the association of myocardial inflammation with platelet activation.

Myocardial inflammation triggered by virus infiltration is associated with endothelial dysfunction that significantly correlates with the expression of myocardial adhesion molecules [12]. Abnormalities of myocardial endothelial cell function lead to impaired nitric oxide synthesis with activating effects on platelets in patients with CMs [30]. Moreover, endothelial cell damage associated with elevated expression of procoagulant factors such as thrombomodulin or soluble selectin have been observed in patients with impaired heart function [31]. Nevertheless, myocardial inflammation seems to be associated with a hypercoagulable condition that leads to an increased risk for ventricular thrombus formation in cases of acute myocarditis [32]. The clinical observation was supported by findings in different murine myocarditis models that confirmed the higher incidence of cardiac thrombus formation [33]. In a murine model acute viral myocarditis was associated with increased myocardial tissue factor expression. Tissue factor contributes to a hypercoagulable state and its expression in cardiac myocytes is anti-apoptotic under inflammatory stress [34–36]. Therefore, we here described a direct relation between myocardial inflammation documented as increased CD3+ T cell infiltration and elevated interstitial/endothelial activation

and platelet dysfunction. Thus, we hypothesized that myocardial inflammation, especially endothelial activation, would be associated with increased platelet activation and an accompanying increased risk for ventricular thrombus formation. This association was independent of hemodynamic values as well as age or gender. Our data support the importance of assessing myocardial inflammation to determine the thromboembolic risk of patients with CMs.

In conclusion, we demonstrated for the first time a significant impact of myocardial inflammation on platelet dysfunction independently of the hemodynamic conditions in patients with CM.

Disclosures

None.

Acknowledgments

Peter Bobbert was supported by “Friedrich C. Luft” Clinical Scientist Pilot Program funded by Volkswagen Foundation and Charité Foundation. The study was supported by grants from the DFG-Sonderforschungsbereich SFB-TR19.

References

- [1] Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. *Circulation* 2000;102:611–6.
- [2] Chesebro JH, Ezekowitz M, Badimon L, Fuster V. Intracardiac thrombi and systemic thromboembolism: detection, incidence, and treatment. *Annu Rev Med* 1985;36:579–605.
- [3] Schultheiss HP, Noutsias M, Kuhl U, Gross U, Lassner D, Poller W, Pauschinger M. Cardiomyopathies II. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy. *Internist (Berl)* 2005;46:1373–85.
- [4] Schultheiss HP, Noutsias M, Kuhl U, Lassner D, Gross U, Poller W, Pauschinger M. Cardiomyopathies. I: classification of cardiomyopathies-dilated cardiomyopathy. *Internist (Berl)* 2005;46:1245–56.
- [5] Witt BJ, Brown Jr RD, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, Roger VL. Ischemic stroke after heart failure: a community-based study. *Am Heart J* 2006;152:102–9.
- [6] Smadja DM, Bura A, Szymezak J, Blanchard A, Remones V, Azizi M, Gaussem P. Effect of clopidogrel on circulating biomarkers of angiogenesis and endothelial activation. *J Cardiol* 2012;59:30–5.
- [7] Lip GY, Piotronikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen LH, Marin F, Lane DA. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. An Executive Summary of a joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. *Thromb Haemost* 2012;108:1009–22.
- [8] Chesebro JH, Rauch U, Fuster V, Badimon JJ. Pathogenesis of thrombosis in coronary artery disease. *Haemostasis* 1997;27(Suppl. 1):12–8.
- [9] Elsherbiny IA, Shoukry A, El Tahlawi MA. Mean platelet volume and its relation to insulin resistance in non-diabetic patients with slow coronary flow. *J Cardiol* 2012;59:176–81.
- [10] Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. *Ann Intern Med* 2001;134:224–38.
- [11] Chung I, Lip GY. Platelets and heart failure. *Eur Heart J* 2006;27:2623–31.

- [12] Vallbracht KB, Schwimmbeck PL, Kuhl U, Rauch U, Seeberg B, Schultheiss HP. Differential aspects of endothelial function of the coronary microcirculation considering myocardial virus persistence, endothelial activation, and myocardial leukocyte infiltrates. *Circulation* 2005;111:1784–91.
- [13] Weikert U, Kuhl U, Schultheiss HP, Rauch U. Platelet activation is increased in patients with cardiomyopathy: myocardial inflammation and platelet reactivity. *Platelets* 2002;13:487–91.
- [14] Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, Olsen Jr EG, Schoen FJ. Myocarditis A histopathologic definition and classification. *Am J Cardiovasc Pathol* 1987;1:3–14.
- [15] Noutsias M, Rohde M, Block A, Klippert K, Lettau O, Blunert K, Hummel M, Kuhl U, Lehmkuhl H, Hetzer R, Rauch U, Poller W, Pauschinger M, Schultheiss HP, Volk HD, et al. Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. *BMC Mol Biol* 2008;9:3.
- [16] Bobbert P, Scheibenbogen C, Jenke A, Kania G, Wilk S, Krohn S, Stehr J, Kuehl U, Rauch U, Eriksson U, Schultheiss HP, Poller W, Skurk C. Adiponectin expression in patients with inflammatory cardiomyopathy indicates favourable outcome and inflammation control. *Eur Heart J* 2011;32:1134–47.
- [17] Noutsias M, Seeberg B, Schultheiss HP, Kuhl U. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. *Circulation* 1999;99:2124–31.
- [18] Rauch U, Schwippert B, Schultheiss HP, Tschöpe D. Platelet activation in diabetic microangiopathy. *Platelets* 1998;9:237–40.
- [19] Piorkowski M, Weikert U, Schwimmbeck PL, Martus P, Schultheiss HP, Rauch U. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. *Thromb Haemost* 2004;92:614–20.
- [20] Piorkowski M, Priess J, Weikert U, Jaster M, Schwimmbeck PL, Schultheiss HP, Rauch U. Abciximab therapy is associated with increased platelet activation and decreased heparin dosage in patients with acute myocardial infarction. *Thromb Haemost* 2005;94:422–6.
- [21] Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss HP, Rauch U. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets. *J Am Coll Cardiol* 2007;49:1035–42.
- [22] Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. *N Engl J Med* 2012;366:1859–69.
- [23] Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. *Circulation* 2009;119:1616–24.
- [24] Alberts VP, Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Stricker BH, Breteleur MM. Heart failure and the risk of stroke: the Rotterdam Study. *Eur J Epidemiol* 2010;25:807–12.
- [25] Witt BJ, Gami AS, Ballman KV, Brown Jr RD, Meverden RA, Jacobsen SJ, Roger VL. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. *J Card Fail* 2007;13:489–96.
- [26] Albers GW, Amarencu P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008;133:630S–69S.
- [27] Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation* 2009;119:1977–2016.
- [28] Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. *Eur Heart J* 1993;14:205–12.
- [29] Mazzone M, La SM, Portale G, Ursella S, Forte P, Carbone L, Testa A, Pignataro G, Covino M, Gentiloni SN. Review of dilated cardiomyopathies. Dilated cardiomyopathies and altered prothrombotic state: a point of view of the literature. *Panminerva Med* 2005;47:157–67.
- [30] Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, Drexler H. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. *Eur Heart J* 2005;26:65–9.
- [31] Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. *Circulation* 2004;110:1794–8.
- [32] Kojima J, Miyazaki S, Fujiwara H, Kumada T, Kawai C. Recurrent left ventricular mural thrombi in a patient with acute myocarditis. *Heart Vessels* 1988;4:120–2.
- [33] Kishimoto C, Ochiai H, Sasayama S. Intracardiac thrombus in murine Coxsackievirus B3 myocarditis. *Heart Vessels* 1992;7:76–81.
- [34] Antoniak S, Boltzen U, Riad A, Kallwellis-Opara A, Rohde M, Dorner A, Tschöpe C, Noutsias M, Pauschinger M, Schultheiss HP, Rauch U. Viral myocarditis and coagulopathy: increased tissue factor expression and plasma thrombogenicity. *J Mol Cell Cardiol* 2008;45:118–26.
- [35] Boltzen U, Eisenreich A, Antoniak S, Weithaeuser A, Fechner H, Poller W, Schultheiss HP, Mackman N, Rauch U. Alternatively spliced tissue factor and full-length tissue factor protect cardiomyocytes against TNF-alpha-induced apoptosis. *J Mol Cell Cardiol* 2012;52:1056–65.
- [36] Rauch U. Tissue factor and cardiomyocytes. *Thromb Res* 2012;129 (Suppl. 2):S41–3.